Mark P. Lythgoe

2.0k total citations
68 papers, 923 citations indexed

About

Mark P. Lythgoe is a scholar working on Oncology, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, Mark P. Lythgoe has authored 68 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Economics and Econometrics and 13 papers in Molecular Biology. Recurrent topics in Mark P. Lythgoe's work include Economic and Financial Impacts of Cancer (18 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Mark P. Lythgoe is often cited by papers focused on Economic and Financial Impacts of Cancer (18 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Mark P. Lythgoe collaborates with scholars based in United Kingdom, United States and Canada. Mark P. Lythgoe's co-authors include Paul Middleton, Vinay Prasad, Jonathan Krell, David J. Benjamin, D. J. Lewis, Adam E. Frampton, Philip Savage, Maximilian Julve, Ali Raza Khaki and Jeremy L. Warner and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Mark P. Lythgoe

60 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark P. Lythgoe United Kingdom 15 257 253 163 162 130 68 923
Ariel Hammerman Israel 15 185 0.7× 348 1.4× 181 1.1× 159 1.0× 79 0.6× 63 1.2k
Subramanian Shankar India 19 140 0.5× 208 0.8× 220 1.3× 104 0.6× 203 1.6× 63 1.3k
Zhangkai J. Cheng China 12 100 0.4× 388 1.5× 176 1.1× 55 0.3× 53 0.4× 61 1.1k
Jun Yin United States 18 224 0.9× 109 0.4× 156 1.0× 60 0.4× 49 0.4× 77 887
Ke Wu China 22 342 1.3× 231 0.9× 451 2.8× 97 0.6× 413 3.2× 68 1.5k
Jinjun Jiang China 17 125 0.5× 335 1.3× 222 1.4× 33 0.2× 112 0.9× 37 1.1k
T. Reid United States 18 472 1.8× 163 0.6× 539 3.3× 75 0.5× 122 0.9× 53 1.4k
Louis Dron Canada 15 103 0.4× 76 0.3× 157 1.0× 192 1.2× 68 0.5× 35 1.2k
Harald Enzmann Germany 20 235 0.9× 71 0.3× 364 2.2× 118 0.7× 62 0.5× 88 1.1k

Countries citing papers authored by Mark P. Lythgoe

Since Specialization
Citations

This map shows the geographic impact of Mark P. Lythgoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Lythgoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Lythgoe more than expected).

Fields of papers citing papers by Mark P. Lythgoe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark P. Lythgoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Lythgoe. The network helps show where Mark P. Lythgoe may publish in the future.

Co-authorship network of co-authors of Mark P. Lythgoe

This figure shows the co-authorship network connecting the top 25 collaborators of Mark P. Lythgoe. A scholar is included among the top collaborators of Mark P. Lythgoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark P. Lythgoe. Mark P. Lythgoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Benjamin, David J., Mark P. Lythgoe, & Arash Rezazadeh Kalebasty. (2024). Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO Oncology Practice. 20(4). 457–459. 2 indexed citations
3.
Trapani, Dario, et al.. (2024). As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022. SHILAP Revista de lepidopterología. 3(1). e000410–e000410. 1 indexed citations
4.
Xing, Eric P., et al.. (2024). 1591P Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024. Annals of Oncology. 35. S958–S959. 1 indexed citations
5.
Julve, Maximilian, Mark P. Lythgoe, James R. Larkin, & Andrew J.S. Furness. (2024). Lifileucel: the first cellular therapy approved for solid tumours. Trends in cancer. 10(6). 475–477. 27 indexed citations
6.
Benjamin, David J. & Mark P. Lythgoe. (2023). The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?. Nature Reviews Clinical Oncology. 20(9). 577–578. 7 indexed citations
7.
Benjamin, David J., et al.. (2023). Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate Cancer and Prostatic Diseases. 27(4). 680–685. 1 indexed citations
8.
Lythgoe, Mark P., Grant Lewison, Ajay Aggarwal, et al.. (2023). The rise of immuno-oncology in China: a challenge to western dominance?. The Lancet Oncology. 24(5). 439–441. 13 indexed citations
9.
10.
Gloy, Viktoria, Andreas M. Schmitt, Julian Hirt, et al.. (2023). The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. International Journal of Cancer. 152(12). 2474–2484. 24 indexed citations
11.
Desai, Aakash, Michael Glover, Gavin Hui, et al.. (2022). Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020. Cancer Investigation. 41(1). 43–47. 1 indexed citations
12.
Lythgoe, Mark P., Benjamin H. Mullish, Adam E. Frampton, & Jonathan Krell. (2022). Polymorphic microbes: a new emerging hallmark of cancer. Trends in Microbiology. 30(12). 1131–1134. 21 indexed citations
13.
Lythgoe, Mark P., Daniel Liu, Nicola Annels, Jonathan Krell, & Adam E. Frampton. (2021). Gene of the month: lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology. 74(9). 543–547. 31 indexed citations
14.
Lythgoe, Mark P., Timothée Olivier, & Vinay Prasad. (2021). The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. European Journal of Cancer. 159. 56–59. 1 indexed citations
15.
Lythgoe, Mark P., Jonathan Krell, Laura Kenny, & Ali Raza Khaki. (2021). 157P Racial diversity and reporting in FDA registration trials for breast cancer from 2006 to 2021. Annals of Oncology. 32. S88–S88. 1 indexed citations
16.
Lythgoe, Mark P., Iain A. McNeish, Hani Gabra, et al.. (2020). Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports. 10(1). 3390–3390. 40 indexed citations
17.
18.
Agliardi, Giulia, Ankit Patel, Adriana Romiti, et al.. (2017). CAR T Cells Combined With PD1 Blockade Promote Long-Term Efficacy in a Mouse Model for High Grade Gliomas. UCL Discovery (University College London). 1 indexed citations
19.
Lythgoe, Mark P., et al.. (2016). Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacology & Therapeutics. 164. 195–203. 31 indexed citations
20.
Lythgoe, Mark P.. (1979). The child in care.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 72(4). 4–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ariel Hammerman Breakdown of academic impact, for papers by Subramanian Shankar Breakdown of academic impact, for papers by Zhangkai J. Cheng Breakdown of academic impact, for papers by Jun Yin Breakdown of academic impact, for papers by Ke Wu Breakdown of academic impact, for papers by Jinjun Jiang Breakdown of academic impact, for papers by T. Reid Breakdown of academic impact, for papers by Louis Dron Breakdown of academic impact, for papers by Harald Enzmann
Rankless by CCL
2026